Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.
2003 | 2002 | 2001 | 2000 | Back to main index |
12/18/2000
12/18/2000
12/06/2000
BIOGEN EXECUTES LICENSE AGREEMENT WITH NSGENE A/S FOR NOVEL NEUROTROPHIC PROTEIN
10/17/2000
AVONEX® (Interferon beta-1a) SHOWN TO BE MOST POTENT INHIBITOR FOR KEY MULTIPLE SCLEROSIS ANTIBODY
10/12/2000
10/10/2000
BIOGEN REPORTS THIRD QUARTER RESULTS
10/06/2000
BIOGEN ANNOUNCES REALIGNMENT OF MANAGEMENT POSITIONS
09/20/2000
BIOGEN SAYS THAT JUDGE ENTERS FINAL JUDGMENT ON ALL CLAIMS IN BERLEX LAWSUIT
09/13/2000
BIOGEN AND EOS BIOTECHNOLOGY ANNOUNCE GENOMIC TARGET AND THERAPUTIC ANTIBODY COLLABORATION
08/17/2000
BIOGEN AND ELAN TO COLLABORATE ON DEVELOPMENT AND COMMERCIALIZATION OF ANTEGREN® (natalizumab)
08/15/2000
BIOGEN PRAISES COURT RULING THAT AVONEX® DOES NOT INFRINGE BERLEX
08/09/2000
BIOGEN AND TARGETED GENETICS TO COLLABORATE ON GENE THERAPY RESEARCH
07/11/2000
BIOGEN REPORTS SECOND QUARTER 2000 RESULTS
07/10/2000
BIOGEN APPOINTS PETER N. KELLOGG VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER